

Alzheimer's Phase III TRONTIER Studies of Trontinemab in Early Symptomatic Alzheimer's (MMSE 18-28) to Begin in Hawaii Late 2025.


Trontinemab's Phase Ib/IIa Brainshuttle™ AD study continues to show rapid and robust clearance of amyloid plaques, with 91% becoming amyloid PET negative and ARIA-E remaining <5%, Honolulu, Hawaii 2025 August

According to [Roche](#), Trontinemab is an investigational Brainshuttle bispecific 2+1 amyloid-beta targeting monoclonal antibody specifically engineered for enhanced crossing the blood barrier via active Tfr1 mediated transcytosis at the capillary level.

Trontinemab - a novel Brainshuttle™ antibody targeting Aβ



Active transport across the BBB significantly increases brain penetration and target engagement




brain

In people with AD, trontinemab demonstrated rapid and robust amyloid plaque reduction at relatively low doses (1.8 and 3.6 mg/kg), compared with standard anti-Aβ monoclonal antibodies like Lecanemab and Donanemab (see below). Preliminary results at 3.6 mg/kg reveal further acceleration of amyloid plaque reduction and amyloid negativity in a majority of participants already after 12 weeks of treatment. Sustained low ARIA incidence (no ARIA-E/ARIA-H at 3.6 mg/kg so far) and overall favourable safety and tolerability profile support further investigation in ongoing Brainshuttle™ AD study.

Trontinemab in Alzheimer's disease



Best-in-class potential: fast and highly efficient plaque removal



[NIH Information](#) or

Contact [Hawaii Memory Dis Center](#) & [Alzheimer's Research Unit](#) (808) 564-6141 for more information or info@HawaiiNeuroscience.com

GRADUATE I / II: presentation at CTAD 2022, publication in preparation; Lecanemab CLARITY AD: N Engl J Med 2023; 388:9-21; Donanemab TRAILBLAZER-ALZ-2: JAMA. 2023;330(6):512-527; AD=Alzheimer's disease; CL=Centiloit unit; PET=Positron Emission Tomography; mAb=Monoclonal antibody; Aβ=amyloid beta; Tau=tau protein